CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
BIA 9-1067 non-micronized +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02305316
NCT02305316Phase 1Completed
CompareCT.gov

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers

Bial - Portela C S.A.·interventional·Posted Dec 2, 2014·Updated Aug 21, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 non-micronized and BIA 9-1067 micronized for Parkinson Disease. Completed, enrolled 28 participants.

Detailed Summary

Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2, 2014
Enrollment StartFeb 1, 2014
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.6 years ago

Interventions

BIA 9-1067 non-micronizeddrug

BIA 9-1067 micronizeddrug